CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Tigecyclinedrug
Likely dose
Tigecycline 100 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01401023
NCT01401023N/ACompleted
CompareCT.gov

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

Gary E. Stein, Pharm.D.·interventional·Posted Jul 25, 2011·Updated Jul 10, 2018

In Brief

A clinical study evaluating Tigecycline for Diarrhea and Clostridium Difficile. Completed, enrolled 10 participants across 2 sites.

Detailed Summary

This is a prospective, non-comparative, interventional, observational pilot study of the safety and pharmacokinetics of intravenous (IV) tigecycline in conjunction with standard oral therapy in patients with known mild to severe confirmed Clostridium difficile associated diarrhea (CDAD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiarrhea, Clostridium Difficile
CountriesUnited States
CollaboratorsPfizer

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 25, 2011
Enrollment StartJul 1, 2011
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 14.9 years ago

Interventions

Tigecyclinedrug

: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.